N/A N=271 Evaluation of Safety and Effectiveness of the BioMimics 3D Stent System
Peripheral Arterial Disease
Primary: Primary Safety Endpoint (Freedom From a Composite of Major Adverse Events (MAE) — 268 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=42 The PK and PD of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM
Type 1 Diabetes Mellitus
Primary: Dapagliflozin Maximum Observed Plasma Concentration (Cmax) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set — 69.31; 162.09 ng/mL
N/A N=16 Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer
Prostate Adenocarcinoma · Stage IIA Prostate Cancer · Stage IIB Prostate Cancer
Primary: Tissue Levels of DHT in Prostate Tissue as Measured by Mass Spectometry — 0.6 pg/mg
N/A N=3,281 Alogliptin/Pioglitazone (Liovel) Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Number of Participants Who Experience at Least One Adverse Events — 206 Participants
Phase 1 N=61 Ascending Single Doses of Erenumab (AMG 334) in Healthy Adults and Migraine Patients
Migraine
Primary: Number of Participants With Adverse Events — 10; 2; 1; 6 Participants
N/A N=220 Study to Investigate the Stain Control of Two Stannous Fluoride Dentifrices
Extrinsic Dental Stain · Oral Hygiene
Primary: Overall Modified Lobene Stain Index (MLSI) Mean Score at Week 4 — 1.38; 1.43; 1.42; 1.38 Score on a scale — p=0.2681
Phase 1 N=31 A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia
Chronic Myeloid Leukemia
Primary: Incidence of Dose Limiting Toxicities (DLT) — 0; 0; 0 Number of Incidence
N/A N=2,259 Whey Permeate Study
Malnutrition
Primary: Recovery From Moderate Acute Malnutrition (MAM) — 960; 874 Participants
Phase 2 N=103 LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Non-Small Cell Lung Cancer
Primary: Primary Pharmacokinetics (PK) Parameters of of LDK378 After Daily Oral Dose: AUClast, AUC0-24h, AUCinf — 10100; 3940; 11100 ng*hr/mL
N/A N=68 Optimal Sevoflurane Concentration for Intubation in Combination of Clincal Remifentanil Doses
Postoperative Pain
Primary: EC50 for Successful Intubation in Each Groups — 3.00; 2.00; 1.29 vol%
Phase 3 N=135 A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]
Autosomal Dominant Polycystic Kidney Disease （ADPKD)
Primary: Total Kidney Volume — 1812.38; 1878.82; 1934.14; 2214.28 mL
Phase 2 N=86 A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Leukemia, Lymphocytic, Chronic, B-Cell
Primary: Percentage of Participants With CR Achieved After the Rituximab, Fludarabine, and Cyclophosphamide Regimen — 95.2 Percentage of Participants
Phase 3 N=94 Adductor Canal Block Versus Femoral Nerve Block for Total Knee Arthroplasty
Arthropathy of Knee
Primary: Mean Distance Ambulated at 24 Hours Post Operatively — 70.2; 48.44 feet
N/A N=72 Promoting Patient-Centered Care Through a Heart Failure Simulation Study
Heart Failure
Primary: Mean Differences in Minnesota Living With Heart Failure Questionnaire (MLHFQ) Results — -4.69; -26.59; -29.36; -4.31 score on a scale
N/A N=69 Exercise for Healthy Aging: The Impact of HIV and Aging on Physical Function and the Somatopause
HIV · Inflammation · Obesity
Primary: Time to Rise From a Chair 10 Times (Modified From the Original Short Physical Performance Battery) — -20; -20; -8; -10 percentage change